Loading stock data…
RAPP
$35.84-0.84 (-2.29%)
Market ClosedLast close Jun 9
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rapport Therapeutics, Inc. in the Healthcare sector is trading at $35.84. Wall Street consensus targets $57.10 (10 analysts), implying a +59.3% move over the next 12 months. The stock is currently 15% below its 52-week high of $42.27, remaining 22.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +59.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$35.84
Potential Downside
0%
Whystock Fair Value$35.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$57.10+59.3%
Range$40.00 – $80.00
Fundamentals
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The comp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.75%
Volume
Today's trading volume
256,709
Recent News
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
In late May 2026, analysts BTIG and Truist highlighted Rapport Therapeutics’ RAP-219 program after the company reported progress toward Phase 3 trials, supported by earlier Phase 2a follow-up data. An interesting angle is how RAP-219’s dual focus on epilepsy and bipolar mania, including a planned long-acting injectable, could broaden Rapport’s clinical opportunity set. We’ll now examine how this momentum in RAP-219, particularly its Phase 3 preparation, influences Rapport Therapeutics’...
BTIG Raises its Price Target on Rapport Therapeutics (RAPP)
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 […]
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings
Over the last year, a good number of insiders have significantly increased their holdings in Rapport Therapeutics, Inc...
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock gains.